Microbot Medical Announces Full U.S. Market Release of LIBERTY Robotic System

Key Facts

1Microbot Medical (MBOT) announced the transition from limited market release (LMR) to full market release (FMR) of the LIBERTY Endovascular Robotic System in the U.S.

2The announcement was made during the Society of Interventional Radiology (SIR) Annual Scientific Meeting.

Microbot Medical Inc. (Nasdaq: MBOT) has officially transitioned from a limited market release to a full market release of its LIBERTY Endovascular Robotic System across the United States. The announcement was made during the Society of Interventional Radiology (SIR) Annual Scientific Meeting, marking a significant commercial milestone for the company. This move follows the successful execution of a limited trial phase, demonstrating the system's readiness for broader clinical adoption. The LIBERTY system is designed to streamline endovascular procedures, potentially improving surgical efficiency and patient outcomes. By moving to full commercialization, Microbot Medical aims to capture a larger share of the rapidly evolving endovascular robotics sector. Investors view this transition as a critical step toward consistent revenue generation and long-term growth for the medical technology firm.